Since its discovery in 1986 (24), feline immunodeficiency virus (FIV) has been established as a common and important infection of the domestic cat and as a cause of serious immune impairment (19, 20, 37) . In addition, FIV is emerging as an increasingly relevant model for human AIDS, since the virus is T lymphotropic and the pathogenesis of experimental FIV infection closely parallels that of human immunodeficiency virus (HIV) infection in humans (2, 3, 23, 38) .
Given the role of the CD4 helper T-cell marker as a receptor for HIV infection (12, 21) , the question of whether FIV utilizes the feline homolog of CD4 (fCD4) (1) is of fundamental interest. The fCD4 marker was implicated by the observed decrease in the ratio of fCD4+ to fCD8' cells in FIV infection (2, 3, 17, 23, 34) and the reduced expression of fCD4 following FIV infection of T cells in vitro (35) . However, although fCD4+ T cells are highly susceptible to FIV infection, we found no correlation between the expression of fCD4 on cells and their ability to support the replication of FIV (35) . Furthermore, FIV infects ostensibly fCD4-cells, such as renal cortical cells (38) , macrophages (5), astrocytes (13) , and fCD8+ T cells (4) . We now describe the isolation and characterization of a monoclonal antibody that is capable of blocking FIV infection and recognizes a feline cell surface marker distinct from fCD4 which may comprise all or part of a receptor for FIV.
Monoclonal antibody vpgl5 was selected from a panel raised by immunization of BALB/c mice with purified FIV virions grown in feline thymocytes. The antibody reacted only weakly by enzyme-linked immunosorbent assay (ELISA) against disrupted FIV particles and did not recognize any virus-specific components by immunoblotting (using FIV-infected cell lysates as described previously [18] ). However, the antibody was found to react with the surface of uninfected cells, including cell types susceptible to FIV infection, such as the antigen-specific T-cell line Q201 (35) , the renal cortical cell line CRFK (11), primary feline astrocytes, and the large granular lymphoma cell line MCC (6) (Fig. la) . Two-color flow-cytometric analysis of feline peripheral blood cells showed that a small subset of both fCD4+ (1) and fCD8+ (22) peritoneal lavage with phosphate-buffered saline [PBS] as described elsewhere [30] ) and neutrophils (Fig. 2b) .
Cell surface iodination and immunoprecipitation identified a vpgl5 ligand of 24 kDa. Cells (107) in 200 ,ul of PBS were labelled with 1251, using Iodobeads as described previously (26 pelleted, and incubated with vpgl5 (50 pul of agarose to 100 pul of antibody) for 30 min. The lysate of surface-iodinated cells (50 pI) was then added and incubated at 4°C for 2 h. After washing, the immune complexes were eluted from the beads by boiling and analyzed by gel electrophoresis and autoradiography as previously described (18) . As can be seen from Fig. lb , FIV-susceptible cell lines such as Q201 T cells, CRFK cells, and MCC cells all expressed the 24-kDa protein which was specifically recognized by the vpgl5 antibody. However, neither the nonfeline cell line U937 (31), which is nonpermissive for FIV, nor the feline lymphoma line 3201 (29) , which is relatively resistant to infection (33, 35) , expressed detectable levels of the 24-kDa ligand.
The first indication that the vpgl5 antibody might recognize a receptor for FIV came from the observation that expression of the vpgl5 marker is consistently decreased on FIV-infected cells (Fig. 2c) . Moreover, activation of feline T cells with concanavalin A (ConA) and interleukin-2 (IL-2) increased their susceptibility to FIV infection concomitantly with expression of the vpgl5 marker. Peripheral blood lymphocytes from a specific-pathogen-free cat were cultured at 5 x 105 cells per ml and stimulated with ConA (7.5 pug/ml). Twenty-four hours later, the cells were washed and then incubated in medium containing IL-2 (100 IU/ml). As shown in Fig. 3a , expression of the vpgl5 marker increased from 3% on day 0 to 52% on day 7. Infection with the Glasgow-8 strain of FIV (FIV/GLA-8) (18) was attempted on day 0, 3, or 6 after T-cell activation. Only the day 3 and 6 cultures became infected, as shown by the production of FIV p249ag (Fig. 3b) .
In view of the correlation between vpgl5 marker expression and susceptibility to FIV infection, we investigated whether the antibody could block de novo infection. nance antibody was added to the medium in these blocking experiments as in analogous blocking experiments with HIV (21) . The cells were subcultured 3 days postinfection and were maintained in culture for a week. Samples of culture fluid were taken daily for measurement of p24gag production by ELISA. As shown in Fig. 3c , only the vpgl5 antibody blocked the increase in FIV p243ag, which began at day 4 in the infected cultures. In contrast, the isotype-matched monoclonal anti-fCD4 antibody had no such effect. Similarly, two other anti-fCD4 monoclonal antibodies which recognize different epitopes (28a) had no effect on FIV infection (data not shown).
We extended our analysis to the Petaluma isolate of FIV (FIV/PET) (24), which has a broad host range, also infecting the CRFK cell line (25) . CRFK cells were seeded onto 24-well plates at a concentration of 2 x 105 cells per well and were incubated overnight. The following day, the medium was removed and the cells were incubated at 37°C for 30 min with twofold dilutions of vpg30 and vpgl5, starting at 1/100. The cells were then incubated with a virus suspension culture fluid (derived from FIV/PET-infected CRFK cells) containing antibody solution at 37°C for 30 min. The cells were then washed twice, and medium containing maintenance antibody (1/5 dilution of antibody solution used to treat cells prior to infection) was added. The cultures were maintained for 4 days. FIV infection of the CRFK cells was monitored by immunocytochemical staining to detect p249a3 antigen as described elsewhere (14) . The wells were examined by light microscopy, and the foci of infection expressing p24.ag antigen were counted. As shown in Fig. 3d, However, this study demonstrates that FIV infection can be blocked by an antibody against a cell surface molecule which does not recognize FIV by either ELISA or immunoblotting and which is nonneutralizing. This blocking effect appears to be specific, since antibody vpgl5 does not block infection of feline cells with feline leukemia virus (data not shown) or CD4-transfected feline cells with HIV-2 (22a). The vpgl5 antibody detects a 24-kDa protein which shows no apparent cross-reaction with the fCD4 molecule (1) . A non-fCD4 receptor for FIV has been implicated by previous studies which have shown that FIV can infect cells devoid of detectable fCD4 (4, 5, 13) . While a role for CD4 as an alternative receptor or as a coreceptor for FIV cannot be formally ruled out and while there may be heterogeneity among FIV isolates in receptor specificity, our results indicate the possible existence of a novel non-CD4 receptor for FIV.
Further studies will be aimed at the molecular cloning of the gene encoding the vpgl5 marker and the determination of its role in FIV infection. Characterization of the putative FIV receptor may also help to elucidate the mechanism by which FIV induces long-term depletion of fCD4+ cell numbers (2, 3, 17, 23, 34) and perhaps provide a useful clue to the putative CD4 coreceptors (8, 9) or CD4-independent entry mechanisms (7, 10, 16, 27, 32) which have been implicated in studies with HIV.
